An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Background Prurigo nodularis (PN) is a chronic disease characterized by intensely pruritic,
raised, nodular lesions. Because there are currently no United States Food and Drug …

Background Prurigo nodularis is a chronic, debilitating, and severely pruritic
neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist …

Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules.
The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with≥ 20 …

Background Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …

Introduction: Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by
intensely pruritic, hyperkeratotic nodules distributed on the trunk and extensor surfaces of …

Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic.
Pruritus might have a tremendous impact on patients' quality of life and strongly interfere …

Chronic prurigo (CPG) is a highly burdensome pruritic disease characterized by chronic itch,
a prolonged scratching behavior and the development of localized or generalized …

Background Prurigo nodularis (PN) is a poorly understood, understudied pruritic dermatosis
that reduces quality of life. Objective To characterize the demographics and comorbidities …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …